Amgen Ends Autoimmune Alliance with Kyowa Kirin for Rocatinlimab Amid Safety and Efficacy Concerns on February 02, 2026 Amgen Autoimmune Alliance Dermatitis, Atopic Kyowa Kirin Phase III portfolio prioritization Rocatinlimab +